Compare Stocks: ELTX, RNAC, FATE, and YDES

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ELTX Elicio Therapeutics	$2.50 -2.0%	$3.14	$2.46 ▼ $16.00	$67.02M	1.29	260,578 shs	272,708 shs
FATE Fate Therapeutics	$2.42 -1.2%	$2.64	$0.93 ▼ $3.23	$293.56M	2.54	1.68 million shs	715,335 shs
RNAC Cartesian Therapeutics	$9.12 +0.4%	$9.07	$5.60 ▼ $11.00	$274.72M	0.62	114,687 shs	134,913 shs
YDES YD Bio	$3.67 -2.4%	$2.82	$1.70 ▼ $25.00	$266.17M	N/A	115,993 shs	672,074 shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ELTX Elicio Therapeutics	-1.96%	-16.67%	-20.89%	-81.15%	-75.85%
FATE Fate Therapeutics	-1.22%	-4.72%	-5.84%	+22.22%	+142.00%
RNAC Cartesian Therapeutics	+0.44%	-8.53%	+13.15%	+56.16%	-11.02%
YDES YD Bio	-2.39%	-5.17%	+58.19%	+18.20%	+366,999,900.00%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ELTX Elicio Therapeutics	$2.50 -2.0%	$3.14	$2.46 ▼ $16.00	$67.02M	1.29	260,578 shs	272,708 shs
FATE Fate Therapeutics	$2.42 -1.2%	$2.64	$0.93 ▼ $3.23	$293.56M	2.54	1.68 million shs	715,335 shs
RNAC Cartesian Therapeutics	$9.12 +0.4%	$9.07	$5.60 ▼ $11.00	$274.72M	0.62	114,687 shs	134,913 shs
YDES YD Bio	$3.67 -2.4%	$2.82	$1.70 ▼ $25.00	$266.17M	N/A	115,993 shs	672,074 shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ELTX Elicio Therapeutics	-1.96%	-16.67%	-20.89%	-81.15%	-75.85%
FATE Fate Therapeutics	-1.22%	-4.72%	-5.84%	+22.22%	+142.00%
RNAC Cartesian Therapeutics	+0.44%	-8.53%	+13.15%	+56.16%	-11.02%
YDES YD Bio	-2.39%	-5.17%	+58.19%	+18.20%	+366,999,900.00%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ELTX Elicio Therapeutics	2.50	Moderate Buy	$19.75	690.00% Upside
FATE Fate Therapeutics	2.38	Hold	$5.90	143.80% Upside
RNAC Cartesian Therapeutics	2.57	Moderate Buy	$32.60	257.46% Upside
YDES YD Bio	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest ELTX, RNAC, FATE, and YDES Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/18/2026	ELTX Elicio Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/18/2026	RNAC Cartesian Therapeutics	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$38.00
8/14/2026	FATE Fate Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$6.00 ➝ $8.00
8/14/2026	FATE Fate Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Equal Weight	$2.50 ➝ $3.50
8/14/2026	FATE Fate Therapeutics	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$7.00
8/7/2026	FATE Fate Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/29/2026	ELTX Elicio Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/29/2026	RNAC Cartesian Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
7/14/2026	ELTX Elicio Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
6/30/2026	RNAC Cartesian Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
6/18/2026	ELTX Elicio Therapeutics	LADENBURG THALM/SH SH Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$12.00

(Data available from 9/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ELTX Elicio Therapeutics	N/A	N/A	N/A	N/A	$0.30 per share	N/A
FATE Fate Therapeutics	$6.65M	43.60	N/A	N/A	$1.28 per share	1.89
RNAC Cartesian Therapeutics	$2.80M	98.53	N/A	N/A	($4.14) per share	-2.20
YDES YD Bio	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ELTX Elicio Therapeutics	-$39.57M	-$2.17	N/A	N/A	N/A	N/A	-1,266.43%	-139.94%	11/12/2026 (Estimated)
FATE Fate Therapeutics	-$136.32M	-$1.05	N/A	N/A	N/A	-1,941.09%	-65.08%	-41.73%	10/29/2026 (Estimated)
RNAC Cartesian Therapeutics	-$130.30M	-$5.94	N/A	N/A	N/A	-8,550.65%	N/A	-29.84%	11/5/2026 (Estimated)
YDES YD Bio	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Latest ELTX, RNAC, FATE, and YDES Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	ELTX Elicio Therapeutics	-$0.5375	-$0.43	+$0.1075	-$0.43	N/A	N/A
8/13/2026	Q2 2026	FATE Fate Therapeutics	-$0.2536	-$0.25	+$0.0036	-$0.25	$1.94 million	$2.08 million
8/6/2026	Q2 2026	RNAC Cartesian Therapeutics	-$0.8779	$0.46	+$1.3379	$0.46	$0.18 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ELTX Elicio Therapeutics	N/A	N/A	N/A	N/A	N/A
FATE Fate Therapeutics	N/A	N/A	N/A	N/A	N/A
RNAC Cartesian Therapeutics	N/A	N/A	N/A	N/A	N/A
YDES YD Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ELTX Elicio Therapeutics	1.20	2.77	2.77
FATE Fate Therapeutics	N/A	4.85	4.85
RNAC Cartesian Therapeutics	N/A	7.48	7.48
YDES YD Bio	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ELTX Elicio Therapeutics	35.03%
FATE Fate Therapeutics	97.54%
RNAC Cartesian Therapeutics	86.95%
YDES YD Bio	N/A

Insider Ownership

Company	Insider Ownership
ELTX Elicio Therapeutics	50.90%
FATE Fate Therapeutics	4.74%
RNAC Cartesian Therapeutics	37.20%
YDES YD Bio	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ELTX Elicio Therapeutics	N/A	26.28 million	12.90 million	Not Optionable
FATE Fate Therapeutics	550	119.82 million	114.14 million	Optionable
RNAC Cartesian Therapeutics	64	30.25 million	19.00 million	Optionable
YDES YD Bio	N/A	70.79 million	N/A	N/A

ELTX, RNAC, FATE, and YDES Headlines

Recent News About These Companies

中概股跌幅榜前十，YD Bio Limited(YDES.US)跌22.71%，房多多(DUO.US)跌20.85%

September 1 at 6:15 PM | finet.hkF

YD Bio Ltd (YDES)

September 1 at 7:24 AM | finance.yahoo.com

YD Bio Files First-Half 2026 Results, Reports Improved Equity Position

September 1 at 6:50 AM | tipranks.com

YD Bio Limited Reports First-Half 2026 Financial Results, 315% Revenue Growth and Net Income of $6.7 Million

August 31, 2026 | quiverquant.comQ

YD Bio Limited Reports Unaudited Financial Results for the Six Months Ended June 30, 2026

August 31, 2026 | globenewswire.com

YDES - YD Bio Limited

August 26, 2026 | seekingalpha.com

Yd Bio Limited publie un article de revue évalué par les pairs dans Nutrients et lance deux produits nutraceutiques à Taïwan

August 26, 2026 | zonebourse.comZ

YD Bio Announces Peer-Reviewed Publication in Nutrients, Co-Authored with Physicians from the Taiwan Chronic Disease Healthcare Association and the Future Health Institute

August 25, 2026 | globenewswire.com

YD Bio Launches a Physician-Partnership Initiative in Taiwan with the Announcement of Two Nutraceutical Products in Collaboration with the Taiwan Chronic Disease Healthcare ...

August 11, 2026 | markets.businessinsider.com

YD Bio Launches Physician-Led Nutraceuticals in Taiwan to Build Consumer Health Ecosystem

August 11, 2026 | tipranks.com

YD Bio Highlights Peer-Reviewed Publication on New Computational Framework for Keratoconus Research

August 4, 2026 | markets.businessinsider.com

YD Bio Launches Cross-Border Cancer Testing Pilot with Numia Health to Evaluate Expanded Access to Molecular Diagnostics in Canada

July 28, 2026 | finance.yahoo.com

YD Bio and EG BioMed Conclude Successful Exhibition at BIO Asia-Taiwan 2026, Highlighting Innovations in Ophthalmology, Oncology Diagnostics, and Clinical Services

July 24, 2026 | markets.businessinsider.com

YD Bio Limited

July 15, 2026 | cnn.com

YD Bio Limited Ordinary Shares (YDES) Insider Activity

July 14, 2026 | nasdaq.com

YD Bio Expands U.S. Laboratory Footprint to 46 States, Strengthening DNA-Methylation Early Cancer Detection Operations

July 2, 2026 | globenewswire.com

YD Bio Ltd.

June 25, 2026 | barrons.com

Yd Bio

June 25, 2026 | fool.com

YD Bio Analyst Ratings and Price Targets | NASDAQ:YDES | Benzinga

June 25, 2026 | benzinga.com

YD Bio Limited Reports Financial Results for Full Year 2025, Achieves 17% Revenue Growth and Strategic Advances in Healthcare Innovations

April 30, 2026 | quiverquant.comQ

New MarketBeat Followers Over Time

Media Sentiment Over Time

ELTX, RNAC, FATE, and YDES Company Descriptions

Elicio Therapeutics NASDAQ:ELTX

$2.50 -0.05 (-1.96%)

As of 09/3/2026 04:00 PM Eastern

Angion Biomedica Corp. is a late-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases. Angion Biomedica Corp. is based in UNIONDALE, N.Y.

Fate Therapeutics NASDAQ:FATE

$2.42 -0.03 (-1.22%)

As of 09/3/2026 04:00 PM Eastern

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.

Cartesian Therapeutics NASDAQ:RNAC

$9.12 +0.04 (+0.44%)

As of 09/3/2026 04:00 PM Eastern

Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases. The company develops Descartes-15 to treat Autoimmune diseases, myeloma; and Descartes-33 which is in preclinical development for treatment of autoimmune diseases. Cartesian Therapeutics, Inc. is headquartered in Gaithersburg, Maryland.

YD Bio NASDAQ:YDES

$3.67 -0.09 (-2.39%)

As of 09/3/2026 04:00 PM Eastern

YD Bio Limited is a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ELTX, RNAC, FATE, and YDES Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ELTX, RNAC, FATE, and YDES Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ELTX, RNAC, FATE, and YDES Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ELTX, RNAC, FATE, and YDES Company Descriptions

Elicio Therapeutics NASDAQ:ELTX

Fate Therapeutics NASDAQ:FATE

Cartesian Therapeutics NASDAQ:RNAC

YD Bio NASDAQ:YDES

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ELTX, RNAC, FATE, and YDES Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ELTX, RNAC, FATE, and YDES Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ELTX, RNAC, FATE, and YDES Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ELTX, RNAC, FATE, and YDES Company Descriptions

Elicio Therapeutics NASDAQ:ELTX

Fate Therapeutics NASDAQ:FATE

Cartesian Therapeutics NASDAQ:RNAC

YD Bio NASDAQ:YDES

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools